I'll add that since you are looking at cancer there are a bunch of options available for doing this prioritization. Ultimately you will be reporting the most well supported/interesting candidates, but should also probably report all 50 of those filtered variants in some sort of supplementary material. There may be something interesting there you missed that will be followed up on by other groups after all.
Some of the tools/sites to use for prioritizing include Cosmic (report any known cancer mutations or new mutations in known cancer-associated genes). For predicting functional impacts use several tools, not just one. PolyPhen, EvoD, FATHMM, etc.
Intronic or UTR variants may be doing something but they tend to be much harder to predict. You can do some searching to see if they lie within known miRNA binding sites, which is somewhat reasonable with only a handful of variants.
Thanks Devon, I agree that one has to move to downstream analysis. I am not sure how 3' UTR variation may be predicted to be associated with loss of function.